GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laekna Inc (HKSE:02105) » Definitions » Capex-to-Operating-Cash-Flow

Laekna (HKSE:02105) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Laekna Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Laekna's Capital Expenditure for the six months ended in Dec. 2024 was HK$-1.36 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$-144.05 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Laekna Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Laekna's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laekna Capex-to-Operating-Cash-Flow Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
- - - -

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial - - - - -

Competitive Comparison of Laekna's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Laekna's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Laekna's Capex-to-Operating-Cash-Flow falls into.


;
;

Laekna Capex-to-Operating-Cash-Flow Calculation

Laekna's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2.042) / -297.136
=N/A

Laekna's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.362) / -144.051
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laekna  (HKSE:02105) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Laekna Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Laekna's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Laekna Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 3-2-467, 5 Xingbin Road (Lin Li Center), Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Executives
Yu Yao Yang Ming Gu Quan Tou Zi Ji Jin You Xian Gong Si 2101 Beneficial owner
Zhong Yi Ning Bo Sheng Tai Yuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Orbimed Advisors Iii Limited 2102 Investment manager
Orbimed Asia Partners Iii, L.p. 2102 Investment manager
Orbimed Asia Gp Iii, L.p. 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Lu Chris Xiangyang 2501 Other
Guo Tou Zhao Shang Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin Er Qi You Xian He Huo 2101 Beneficial owner
Laekna Wonderland Limited 2101 Beneficial owner
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Shang Hai Jin Pu Yi Liao Jian Kang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Gp Healthcare Capital, Inc. 2101 Beneficial owner
Liu Zeng 2201 Interest of corporation controlled by you
Ealex Llc 2101 Beneficial owner

Laekna Headlines

No Headlines